Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2025) 110 EP528 | DOI: 10.1530/endoabs.110.EP528

ECEESPE2025 ePoster Presentations Diabetes and Insulin (245 abstracts)

Prevalence of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: a tunisian study

Yesmine Elloumi 1 , Mouna Elleuch 1 , Khouloud Boujelben 1 , Yasmine Abdelkafi 2 , Faten Hadj Kacem 2 , Nadia Charfi 2 , Mouna Mnif 3 , Dhoha Ben Salah 2 & Nabila Rekik Majdoub 2


1Hedi Chaker University Hospital, Sfax, Tunisia; 2Hedi Chaker University Hospital, Endocrinology Department, Sfax, Tunisia; 3Hedi Chaker Univeristy Hospital, Sfax, Tunisia


JOINT422

Background: Metabolic Associated Steatotic Liver Disease (MASLD) is a growing global health concern. The coexistence of MASLD and Type 2 Diabetes Mellitus (T2DM) poses a significant clinical challenge, as both conditions are intertwined through common pathophysiological mechanisms. Understanding the prevalence of MASLD in T2DM patients is crucial for developing effective screening, prevention, and treatment strategies. This study aims to investigate the prevalence of MASLD in T2DM patients.

Methods: This was a retrospective study that included patients followed for T2DM from 2012 to 2024 at the Endocrinology and Diabetology Department of the Hedi Chaker University Hospital in Sfax, Tunisia. The diagnosis of MASLD within T2DM patients was based on the 2024 EASL-EASD-EASO guidelines on the Management of MASLD.

Results: A total of 734 patients with T2DM was recruted and underwent abdominal imaging. 609 patients (83%) had normal imaging results, while 125 patients (17.03%) were diagnosed with hepatic steatosis. Thus, the prevalence of MASLD in our cohort of T2DM patients was found to be 17.03%. The mean age of the diabetic patients with MASLD was 53.7 (±15.2) years, with a female predominance of 62.4%.

Conclusion: Our study provides valuable insights into the burden of this dual diagnosis emphasizing its clinical significance. These findings highlight the critical need for early detection and effective management of MASLD in diabetic patients.

Volume 110

Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025: Connecting Endocrinology Across the Life Course

European Society of Endocrinology 
European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches